>US Stocks>Theriva Biologics

Theriva BiologicsHealthcare

$0.16$-0.12 (-41.99%)in 1 year

As on 13 Nov 2026 at 02:27NYSE

52 Week Low: $0.1452 Week High: $0.49

Theriva Biologics Share Price Today

Theriva Biologics opened lower at $0.15, compared with its previous close of $0.16. In the last trading session, the stock traded between $0.15 and $0.16. It showed a sideways intraday trend.

Return calculator

You have invested

Time Period

An investment of $100 made 5 years ago in Theriva Biologics is now worth

$ 0.62

Resulting in a loss of

$ 99.38 (99.38%)

Invest with $1

Note: Past profits do not guarantee future returns.

Analyst Overview

No analyst rating data available.

Markets Today

Today's Change

$-0.00 (-0.56%)

Day High

$0.16

Day Low

$0.15

Day Open

$0.15

Prev Close

$0.16

Volume

4,96,042

1W Return

-10.61%

1M Return

-28.25%

3M Return

-29.82%

6M Return

-53.08%

1Y Return

-41.99%

Fundamentals

Market Cap ($ Mn)

PE Ratio

0.34

PB Ratio

0.92

PEG Ratio

ROE

-176.35%

ROCE

-97.45%

EPS (TTM)

$-0.07

Investment Returns

1 Week

-10.61%

1 Month

-28.25%

3 Months

-29.82%

6 Months

-53.08%

9 Months

-21.95%

Financials

Quarterly

All values in $ Mn

0.0

Mar 25

0.0

Jun 25

0.0

Sep 25

0.0

Dec 25

0.0

Mar 26

0.0

Jun 26

Updates

11Aug

Theriva Biologics Q2 Results: EPS misses estimates, losses widen 96% YoY

Theriva Biologics missed Q2 EPS estimates with a loss of $(0.07) per share, 40% worse than the $(0.05) consensus. Losses increased 96.37% YoY from $(1.93) per share, reflecting ongoing profitability challenges.

3mo ago

7Jul

Theriva Biologics authorized to initiate VIRAGE2 clinical trial in Spain

Theriva Biologics secured Spanish regulatory authorization to start the VIRAGE2 trial, testing higher frequency dosing of VCN-01 with chemotherapy in metastatic pancreatic cancer. The trial follows positive Phase 2b results where two doses improved survival outcomes. Results will guide dosing strategies for a potential Phase 3 study.

4mo ago

11Jun

Theriva Biologics publishes VCN-01 Phase 1 trial results

Theriva Biologics published Phase 1 trial results for VCN-01 in Head & Neck Squamous Cell Carcinoma, showing prolonged overall survival with sequential durvalumab. Biomarker data confirmed immune reactivation and stroma-degrading mechanisms.

5mo ago

Similar Stocks

Stock	LTP	Change %	Market Cap	PE
V Vertex Pharmaceuticals	$547.03	-0.16%	$1,38,692.89M	31.55
B British American Tobacco	$61.05	+0.38%	$1,31,510.31M	14.39
M Moderna	$248.69	-0.85%	$1,00,625.20M	-
R Regeneron Pharmaceuticals	$959.41	+4.73%	$97,505.80M	19.64
A Argen X SE - ADR	$977.58	+0.62%	$61,476.10M	38.99
O BeOne Medicines - ADR	$419.98	-0.95%	$46,108.31M	65.60
R Revolution Medicines	$180.70	-6.40%	$39,083.96M	-
G Genmab	$53.87	-0.37%	$33,618.11M	26.24
R Royalty Pharma - Class A	$70.01	+0.81%	$31,173.07M	32.37
R Roivant Sciences	$41.85	+1.60%	$30,322.88M	-
I Insmed	$120.75	+1.05%	$26,490.14M	-
I Incyte	$122.27	+1.64%	$24,922.54M	15.85